Global Partners LP — News

Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lower dosage of its weight loss drug Wegovy to the highest dose of its own weight loss drug Zepbound.

fool.com - 2026-07-21 17:34:01

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.

proactiveinvestors.com - 2026-07-21 11:24:07

LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.

zacks.com - 2026-07-21 11:20:30

Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lilly's products.

forbes.com - 2026-07-21 09:15:12

The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs

marketwatch.com - 2026-07-21 08:18:00

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

wsj.com - 2026-07-21 07:58:00

Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy relative to the Danish drugmaker's rival injections.  Novo Nordisk is specifically taking issue with nationwide ads that cite what it called "outdated" clinical trials to compare the highest doses of Lilly's medicines to lower doses of Novo's drugs.

cnbc.com - 2026-07-21 07:35:46

Citi has raised its price target on Novo Nordisk (NYSE:NVO) to DKK330 ahead of second-quarter results on 5 August, citing the strength of the Danish drugmaker's Wegovy pill launch. The broker lifted its 2026 sales and operating income estimates by 4% to 5%, and its earnings per share forecasts for 2027 to 2030 by around 7%, on currency movements and stronger second-quarter Wegovy trends.

proactiveinvestors.co.uk - 2026-07-20 09:35:30

MichaelAaron Flicker examines the growing impact of GLP-1 medications on consumer behavior, noting that roughly one in five American households has someone using a GLP-1 drug. He explains how that trend is reshaping spending habits and discusses the implications for restaurants as well as food and beverage stocks.

youtube.com - 2026-07-18 16:00:15

Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs.

fool.com - 2026-07-18 15:45:00

Novo Nordisk is pulling ahead of Eli Lilly in the market for oral weight loss medicines. Eli Lilly has several tricks up its sleeve that could help it make some progress in this niche.

fool.com - 2026-07-17 14:30:00

Following a careful analysis of the Zacks Oil and Gas - Refining & Marketing MLP industry, we advise keeping an eye on three stocks: SPH, NGL and GLP.

zacks.com - 2026-07-16 10:36:30

Fractyl Health NASDAQ: GUTS reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced weight loss after discontinuing GLP-1 therapy compared with a sham procedure.

marketbeat.com - 2026-07-15 09:03:57

Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026 Company to host investor webcast today at 8:00 a.m. ET BURLINGTON, Mass.

globenewswire.com - 2026-07-15 06:00:00

Potential signs of frailty in older adults taking Eli Lilly's GLP-1 obesity drug Zepbound ​may signal relatively high risks for adverse outcomes, according to a large study that underscores concerns about how best to monitor seniors as U.S. Medicare expands access to ‌GLP-1 therapies.

reuters.com - 2026-07-14 19:08:51

Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.

globenewswire.com - 2026-07-14 08:30:00

Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical, has raised £3.5 million before expenses through a share placing. Cathal Friel, executive chair, subscribed for £250,000 of the placing.

proactiveinvestors.co.uk - 2026-07-14 02:46:29

- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented six-month good laboratory practice (GLP) toxicology data for VY1706, the Company's investigational gene therapy targeting intracellular and extracellular tau for Alzheimer's disease (AD), in a Developing Topics (late-breaking) poster presentation at the Alzheimer's Association International Conference (AAIC) taking place in London, July 12-15, 2026.

globenewswire.com - 2026-07-13 08:01:00

Top-tier U.S. grocery and pharmacy chain launches 662-store GLP-1 pharmacy merchandising One of North America's largest omnichannel retailers approves onboarding of Rejuvenate's complete eight-SKU portfolio Burlington, Ontario--(Newsfile Corp. - July 13, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") a muscle health company with distribution in more than 10,000 retail locations across North America, is pleased to announce two commercial achievements for Rejuvenate Muscle Health™ that further expand the brand's retail and e-commerce presence in the United States. Effective June 12, 2026, the Company has been selected by one of the largest grocery and pharmacy retailers in the United States for a 662-store pharmacy merchandising program focused on consumers using GLP-1 medications.

newsfilecorp.com - 2026-07-13 07:00:00

Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech company is in the early stages of developing an experimental implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.

cnbc.com - 2026-07-11 08:00:01

Plus, how fitness trackers stack up against each other and the popularity of panic pouches.

wsj.com - 2026-07-10 12:55:00

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.

247wallst.com - 2026-07-09 08:00:59

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging.

247wallst.com - 2026-07-08 12:02:52

Shares in Novo Nordisk (NYSE:NVO) fell 2.5% to DKK319.20 after Deutsche Bank pointed to a continued slowdown in the oral version of the company's Wegovy weight-loss drug in the US. The bank published its weekly tracker of prescription data for Novo's GLP-1 franchise, the class of appetite-suppressing treatments that has driven the company's growth.

proactiveinvestors.co.uk - 2026-07-08 10:39:20

Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.

fool.com - 2026-07-07 17:30:00

Eli Lilly's growth rate has been accelerating over the past year due to its GLP-1 drugs. The recent approval of its GLP-1 pill, Foundayo, could offer yet another catalyst.

fool.com - 2026-07-07 11:00:00

Kailera ​Therapeutics said ‌on ​Tuesday ​its GLP-1 ⁠drug ​for patients ​with diabetes ​and ​obesity met the ‌main ⁠goal of ​two-late ​stage ⁠trials.

reuters.com - 2026-07-07 07:09:07

Nestle is looking to spice up some of its products to counter duller taste buds that can accompany GLP-1 weight-loss drugs.

wsj.com - 2026-07-07 06:32:00

Lower crude prices have reset energy-sector expectations, making GLP, NESR and IMO buy candidates for investors seeking oil-linked opportunities.

zacks.com - 2026-07-06 09:01:22

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD.

newsfilecorp.com - 2026-07-06 08:00:00

VANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce continued progress in its sublingual Semaglutide oral dissolvable film ("ODF") program, marking the next stage of development for the Company's GLP-1 delivery platform. Expanding BioNxt's Thin-Film Platform into GLP-1 Therapeutics BioNxt's Semaglutide ODF program is designed to evaluate a needle-free, patient-friendly thin-film delivery format for GLP-1 receptor agonists, a class of therapeutics widely used in the treatment of type 2 diabetes, obesity, weight management, and related metabolic disorders.

accessnewswire.com - 2026-07-06 03:05:00

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

zacks.com - 2026-07-03 10:16:08

Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.

fxempire.com - 2026-07-01 10:23:11

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

zacks.com - 2026-07-01 09:16:09

Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk's oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs' commercial potential and raising the value of VKTX's oral program. VKTX's injectable VK2735 faces intensified competition after Eli Lilly's Retatrutide Phase III results, which establish a higher efficacy standard (>24%).

seekingalpha.com - 2026-06-30 14:32:38

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.

zacks.com - 2026-06-30 11:25:20

Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program. Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program.

globenewswire.com - 2026-06-30 08:00:00

Eli Lilly could capitalize on the growing GLP-1 market and deliver strong returns through 2031. However, investors need to keep several risks in mind.

fool.com - 2026-06-30 03:00:00

WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global”) today announced that it intends to redeem all $75,000,000 of its 3,000,000 issued and outstanding Series B Fixed Rate Cumulative Redeemable Perpetual Preferred Units (the “Series B Preferred Units”) (CUSIP: 37946R307). All of the Series B Preferred Units are maintained in book-entry form registered in the name of The Depository Trust Company or its nominee and will be redeemed in accordance with the applicable procedures.

businesswire.com - 2026-06-29 16:05:00

Citi has said Novo Nordisk's (NYSE:NVO) Wegovy pill is outpacing its rivals in the United States, even as competition in the oral weight-loss market intensifies. The broker's prescription tracker showed the oral version of Wegovy reached around 152,000 US prescriptions in its 24th week of launch, in the week ending 19 June.

proactiveinvestors.co.uk - 2026-06-29 04:58:58

CVS Health announced a program to help patients get easier access to GLP-1 medicines. This initiative could lead to stronger revenue for the company.

fool.com - 2026-06-27 00:30:00

We also report on a potentially simple solution to ​nausea experienced by cancer patients receiving morphine for pain.

reuters.com - 2026-06-26 10:45:46

Kelowna, British Columbia – June 25, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14 th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo Nordisk's® (“Novo”) commercially available Wegovy® tablets, over a 5-week duration (the “Study”).   Lexaria is seeking to preserve the superior safety and tolerability profiles evidenced in its previous glucagon-like peptide-1 (“GLP-1”) studies such as Human Study #4 (GLP-1-H24-4 ), combined with pharmacokinetic (“PK”) performance that matches or exceeds the Wegovy® tablet control.  Previous Lexaria salcaprozate sodium (“SNAC”)-inclusive DHT-sema single dose studies such as Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2 ) evidenced PK performance that matched or exceeded the Rybelsus® control arm and also evidenced noteworthy safety and tolerability profiles.

thenewswire.com - 2026-06-25 09:10:00

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is supporting the more than 56 million patients in the Medicare network that may be eligible for GLP-1 medications through the Medicare GLP-1 Bridge program. Walgreens pharmacists will help eligible Medicare patients navigate the new program at nearly 8,000 stores across the country. To get started, patients should speak with their healthcare provider about whether they may be eligible. The Medicare Bridge program is a new nationwide initiative from t.

businesswire.com - 2026-06-25 08:00:00

UBS says the market for GLP-1 obesity and diabetes drugs remains structurally strong, with obesity the key driver of growth, in a note backing its positive stance on the sector's key suppliers. The bank, drawing on a call with its US biotech analyst Michael Yee, put the global market at around $130 billion to $135 billion by 2030.

proactiveinvestors.co.uk - 2026-06-24 09:08:39

Global Partners (GLP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com - 2026-06-24 04:01:03

Eli Lilly's orforglipron type-2 diabetes and obesity pill could launch in China as soon as later this year, ​an executive at the U.S. drugmaker told Reuters, as rival ‌Novo Nordisk seeks to catch up in the world's second-largest drug market.

reuters.com - 2026-06-24 02:36:24

Eli Lilly is already a market leader in the GLP-1 market, but its high valuation could limit future gains. Viking Therapeutics doesn't have an approved product just yet, but VK2735 has shown a lot of promise in clinical trials.

fool.com - 2026-06-23 10:14:00

Potentially valuable novel compositions being investigated Lexaria also receives additional new granted patent

thenewswire.com - 2026-06-23 09:25:00

Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug Administration (FDA)-authorized tirzepatide once-weekly formulation.

prnewswire.com - 2026-06-23 06:10:00